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1. Introduction 
Thyrotropic hormone (TSH) controls thyroid hor- 
mone synthesis and secretion through the activation 
of the adenylate cyclase and the increase of the intra- 
cellular level of CAMP (see references in [ 11). The 
CAMP formed, activates the CAMP-dependent protein 
kinases [2-51. If TSH stimulation is prolonged, modi- 
fications were also observed in the ratios between the 
two protein kinase isoenzymes present in thyroid 
cytosol (type I and type II). It was thus demonstrated 
that in chronically stimulated rat thyroid glands the 
activity of type II kinase is selectively increased [6-81. 
The modifications of ratios between type I and type II 
protein kinases were also noted during the cell cycle 
of cultured Chinese hamster ovary cells [9-l 11, during 
the differentiation and postnatal development of 
several organs [ 12-151, after stimulation of different 
tissues by trophic hormones [ 16-231 as well as in 
some tumoral tissues [24] and transformed cells [25]. 
All these findings suggest hat the two isoenzymes of 
CAMP-dependent protein kinases could have different 
biological functions, and that their activity may be 
controled by separate and distinct mechanisms, as was 
demonstrated for enzymes from rabbit uterus [26]. 
Here, we were interested to see whether and how 
the CAMP-dependent protein kinases are modified in 
human thyroids expressing different troubles of hor- 
monogenesis. Our results showed that, with respect to 
normal glands, the alterations of the ratios between 
the two CAMP-dependent protein kinase isoenzymes, 
and their different subcellular distributions occured 
in several types of pathological tissues. The observed 
quantitative changes were due to the selective modi- 
ElsevierfNorth-Holland Biomedical Press 
fications of the type I protein kinase activity: in toxic 
adenoma this activity was significantly inhibited, while 
in non-toxic adenoma it was stimulated, with respect 
to control tissues. These data suggest hat CAMP-de- 
pendent protein kinases could be involved in the 
mechanism of different thyroidal troubles in a very 
specific and selective way. 
2. Material and methods 
Immediately after excision, glands were frozen and 
stored at -80°C until used. Thawed glands were 
cleaned from fibrous and other adjacent tissues, and 
homogenized in 15 vol. (w/v) 50 mM Tris-HCl buffer 
(PH 7.4) containing: 2.5 mM KCl, 5mM MgClz ,3 mM 
mercaptoethanol and 0.25 M sucrose, under the same 
conditions as for rat glands 16,271. After separation 
of cytosol, and prior to analysis, the particulate en- 
zymes were solubilized with Nonidet P 40: 0.5% final 
cont. (w/v) in the homogenization buffer, for 1 h at 
4”C, followed by dilution of Nonidet to 0.3% and 
centrifugation for 1 h at 50 000 rev./min, Rotor 50. 
This solubilized the totality of particulate CAMP- 
dependent protein kinases. 
Here, we analyzed the protein kinase activity in 2 
pieces from normal glands, 3 pieces from colloid 
nodular goiters, 2 toxic adenomas and 1 non-toxic 
adenoma. Toxic adenomas were hot nodules with in- 
creased iodine uptake and metabolism. The non-toxic 
adenoma was a hot nodule with increased uptake of 
iodine, which was, however, almost completely dis- 
charged by the perchlorate, indicating that iodine, 
taken up by the nodule, was not further metabolized. 
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All nodules were identified by clinical and histological 
criteria. They were always surrounded by a thick fi- 
brous capsule. 
All other techniques (cytosol fractionation and 
protein kinase determination) have been described in 
[6,27]. Results are expressed either in % of total acti- 
vity determined for each type of tissue (pmol 32P in- 
corporated into histone/mg tissue in 5 min incubation), 
or relatively, with respect to control tissue (normal 
glands). 
3. Results and discussion 
Tissue 
Normal 
Non-toxic 
adenoma 
Toxic 
adenoma 
Colloid nodular 
goiter 
ap < 0.02; bP < 0.001 
(ii) Qualitative and quantitative differences in the 
In thyroid gland cytosols the two CAMP-dependent subcellular distribution of the two types of kinases 
protein kinases (types &II) have been identified by were noted. In both, colloid nodular goiters and 
several authors [7,27-301. Their relative activities toxic adenomas the proportion of particulate en- 
depended on the origin of tissue (species) and the hor- zymes was increased significantly (table 1). More- 
monal status of the glands [6-81. over, while in normal glands and in non-toxic 
In pathological tissues, analyzed here, 3 main modi- adenoma, type I kinase was found almost exclu- 
fications of CAMP-dependent protein kinases were sively; in colloid nodular goiters and in toxic 
observed: adenomas 2 peaks of protein kinase activity were 
G) Ratios between type I and type II protein kinases present in the particulate fraction (fig.2). 
were significantly different, depending on the (iii) The estimation of quantitative difference between 
origin of tissue: in normal tissue and in non-toxic normal and pathological tissues was possible only 
adenoma type I kinase was predominant; in toxic in 2 cases in which both tissues were obtained 
adenomas the two kinases were found in the same from the same patient: in the case of non-toxic 
proportions; while in colloid nodular goiters 
kinase II was preponderant (fig.1). 
q-----A” I I I C 15 
100 r _lo 
A 6 c Fig.2. Sucrose gradient ultracentrifugation patterns of parti- 
culate protein kinases solubilized from: (A) normal tissue; 
Fig.1. Relative activities of type I ( m ) and type (B) coUoid nodular goiter; (C) toxic adenoma; (D) non-toxic 
II ( i-1 ) protein kinases in: (A) normal tissues; adenoma. Results are expressed in % of total particulate 
(B) toxic adenomas; (C) colloid nodular goiters. activity. 
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Table 1 
Particulate protein kinase activity 
Percent of total activity 
7.5 + 0.8 
8.4 ?; 1.0 
17.9 + 3.2a 
16.2 + 1.4b 
10 
top 
20 30 40 10 20 30 40 
FRACTIONS 
bottom 
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Table 2 
Quantitative evaluation of protein kinase activity (pmol 
s*P . mg tissue-’ .5 min-’ ) in non-toxic and toxic adenomas 
nodule, but were propagated also to the extracapsular 
tissue. 
Totala Type I Type II 
Control 
Non-toxic 
adenoma 
Percent 
of control 
21.3 15.9 5.4 
32.2 26.5 5.1 
151 167 106 
Control 
Toxic 
adenoma 
Percent 
of control 
48.8 33.8 15.0 
28.5 12.6 15.9 
58.4 31.3 106 
We still do no know either the exact role of the 
two kinases, or the mechanism by which they control 
thyroid hormone synthesis and secretion, the impor- 
tant changes of these enzyme activities observed in 
different pathological tissues suggest hat some thy- 
roidal troubles could be due not only to modifications 
of enzymes directly involved in the hormonogenesis, 
like peroxidase [31-331, but also to the alterations 
of the regulatory enzymes, like protein kinases, which 
control the phosphorylation of different thyroid cell 
proteins. 
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